MX349145B - Formulaciones orales y sales lipofilicas de metilnaltrexona. - Google Patents
Formulaciones orales y sales lipofilicas de metilnaltrexona.Info
- Publication number
- MX349145B MX349145B MX2012009125A MX2012009125A MX349145B MX 349145 B MX349145 B MX 349145B MX 2012009125 A MX2012009125 A MX 2012009125A MX 2012009125 A MX2012009125 A MX 2012009125A MX 349145 B MX349145 B MX 349145B
- Authority
- MX
- Mexico
- Prior art keywords
- methylnaltrexone
- oral formulations
- lipophilic salts
- lipophilic
- salts
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical class C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 229960002921 methylnaltrexone Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31301810P | 2010-03-11 | 2010-03-11 | |
| PCT/US2011/027913 WO2011112816A1 (en) | 2010-03-11 | 2011-03-10 | Oral formulations and lipophilic salts of methylnaltrexone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012009125A MX2012009125A (es) | 2012-09-07 |
| MX349145B true MX349145B (es) | 2017-07-14 |
Family
ID=44148539
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012009125A MX349145B (es) | 2010-03-11 | 2011-03-10 | Formulaciones orales y sales lipofilicas de metilnaltrexona. |
| MX2015010803A MX368805B (es) | 2010-03-11 | 2011-03-10 | Formulaciones orales y sales lipofílicas en metilnaltrexona. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010803A MX368805B (es) | 2010-03-11 | 2011-03-10 | Formulaciones orales y sales lipofílicas en metilnaltrexona. |
Country Status (32)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1615646T4 (da) | 2003-04-08 | 2022-10-10 | Progenics Pharm Inc | Farmaceutiske formuleringer, der indeholder methylnaltrexon |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| CA2945356C (en) | 2007-03-29 | 2021-03-23 | Progenics Pharmaceuticals, Inc. | (r)-n-methylnaltrexone bromide and pharmaceutical compostitions therof useful as peripheral .mu. opioid receptor antagonist |
| US9061076B2 (en) | 2007-05-25 | 2015-06-23 | North Carolina State University | Viral nanoparticle cell-targeted delivery platform |
| CN107308125B (zh) | 2010-03-11 | 2021-07-16 | 惠氏有限责任公司 | 甲基纳曲酮的口服制剂和亲脂盐 |
| US8627816B2 (en) | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| WO2013096444A1 (en) * | 2011-12-19 | 2013-06-27 | Salix Pharmaceuticals, Ltd. | Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone |
| WO2015191686A1 (en) * | 2014-06-10 | 2015-12-17 | Salix Pharmaceuticals, Inc. | Methods of administering methylnaltrexone |
| US10722510B2 (en) * | 2014-07-08 | 2020-07-28 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US10617686B2 (en) * | 2014-07-08 | 2020-04-14 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US10441538B2 (en) * | 2014-07-08 | 2019-10-15 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| JP2017519803A (ja) * | 2014-07-08 | 2017-07-20 | インシス・ファーマ・インコーポレーテッド | 舌下ナロキソンスプレー |
| JP6686013B2 (ja) | 2014-10-17 | 2020-04-22 | サリックス ファーマスーティカルズ，インコーポレーテッド | 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用 |
| WO2020128583A1 (en) * | 2018-12-19 | 2020-06-25 | Friulchem S.P.A. | Process for the manufacture of a tablet of rifaximin and tablet of rifaximin |
| EP3965731A1 (en) * | 2019-05-07 | 2022-03-16 | Bausch Health Ireland Limited | Liquid oral dosage formulations of methylnaltrexone |
| WO2020245214A1 (en) | 2019-06-03 | 2020-12-10 | Bausch Health Ireland Limited | Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders |
| WO2021224138A1 (en) | 2020-05-02 | 2021-11-11 | Bausch Health Ireland Limited | Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone |
| WO2023031955A1 (en) * | 2021-08-28 | 2023-03-09 | Redasani Vijayendrakumar Virendrakumar Ji | Oral pharmaceutical compositions of methylnaltrexone and salt thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
| US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| CA1297218C (en) | 1986-03-14 | 1992-03-10 | Edward David Weil | Thermally stable diphosphonate-type flame retardant additive for plastics |
| US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
| US5780012A (en) | 1990-06-21 | 1998-07-14 | Huland; Edith | Method for reducing lung afflictions by inhalation of cytokine solutions |
| AU5171293A (en) | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
| US5866154A (en) | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
| DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
| SK282549B6 (sk) | 1997-02-14 | 2002-10-08 | G�decke Aktiengesellschaft | Spôsob stabilizácie naloxonhydrochloridu |
| ATE210983T1 (de) | 1997-11-03 | 2002-01-15 | Stada Arzneimittel Ag | Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum |
| US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
| US20030158220A1 (en) | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
| US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| GB0100115D0 (en) | 2001-01-04 | 2001-02-14 | Alchemia Pty Ltd | Delivery systems |
| ES2361148T3 (es) * | 2001-05-11 | 2011-06-14 | Endo Pharmaceuticals Inc. | Forma de dosificación de opioides de liberación controlada resistente al abuso. |
| EP1404323B1 (en) | 2001-06-05 | 2009-10-28 | The University of Chicago | Use of methylnaltrexone to treat immune suppression |
| JP4814488B2 (ja) | 2001-10-18 | 2011-11-16 | ネクター セラピューティックス | 重合体共役物オピオイドアンタゴニスト |
| CN1596254A (zh) * | 2001-11-29 | 2005-03-16 | 先灵公司 | 含有增加量的旋转异构体的药物活性盐的组合物的制备方法 |
| MXPA04008772A (es) | 2002-03-14 | 2004-12-06 | Euro Celtique Sa | Composiciones de clorhidrato de naltrexona. |
| US20030191147A1 (en) | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
| EP1617846A1 (en) | 2003-04-08 | 2006-01-25 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| CA2521420A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
| DK1615646T4 (da) | 2003-04-08 | 2022-10-10 | Progenics Pharm Inc | Farmaceutiske formuleringer, der indeholder methylnaltrexon |
| EP2462896A1 (en) * | 2003-07-15 | 2012-06-13 | PR Pharmaceuticals Inc. | Method for the preparation of controlled release formulations |
| US8946262B2 (en) | 2003-12-04 | 2015-02-03 | Adolor Corporation | Methods of preventing and treating gastrointestinal dysfunction |
| CN100528162C (zh) | 2003-12-19 | 2009-08-19 | 先灵公司 | 药物组合物 |
| WO2005065656A2 (en) * | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers |
| CN1294728C (zh) | 2004-08-05 | 2007-01-10 | 华为技术有限公司 | 边缘路由器提供服务质量保证的方法及系统 |
| ES2392645T3 (es) | 2004-09-30 | 2012-12-12 | Becton,Dickinson And Company | Método para reducir o eliminar residuos en una recipiente médico de vidrio y recipiente hecho de acuerdo con el mismo |
| US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| TWI489984B (zh) * | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| WO2008021394A2 (en) * | 2006-08-15 | 2008-02-21 | Theraquest Biosciences, Llc | Pharmaceutical formulations of cannabinoids and method of use |
| WO2008021349A1 (en) * | 2006-08-16 | 2008-02-21 | Novartis Ag | Temporal photo-bleaching of colored lens care solutions and use thereof |
| JP2010506833A (ja) * | 2006-10-11 | 2010-03-04 | アルファーマ，インコーポレイテッド | 医薬組成物 |
| TW200843802A (en) | 2007-02-09 | 2008-11-16 | Drugtech Corp | Compositions for improving gastrointestinal nutrient and drug absorption |
| JP5469593B2 (ja) | 2007-03-29 | 2014-04-16 | ワイス・エルエルシー | 末梢性オピオイド受容体アンタゴニストおよびその使用 |
| CA2945356C (en) * | 2007-03-29 | 2021-03-23 | Progenics Pharmaceuticals, Inc. | (r)-n-methylnaltrexone bromide and pharmaceutical compostitions therof useful as peripheral .mu. opioid receptor antagonist |
| JP5178064B2 (ja) * | 2007-06-27 | 2013-04-10 | 富士フイルム株式会社 | 金属表面粗化層を有する金属層積層体及びその製造方法 |
| KR20110004425A (ko) * | 2008-05-07 | 2011-01-13 | 넥타르 테라퓨틱스 | 말초적 작용 오피오이드 길항제의 경구 투여 |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| JP5525247B2 (ja) * | 2009-08-04 | 2014-06-18 | 株式会社神戸製鋼所 | 高強度で曲げ加工性に優れた銅合金 |
| CN107308125B (zh) | 2010-03-11 | 2021-07-16 | 惠氏有限责任公司 | 甲基纳曲酮的口服制剂和亲脂盐 |
| TW201235609A (en) * | 2010-07-13 | 2012-09-01 | Koninkl Philips Electronics Nv | Low cost mounting of LEDs in TL-retrofit tubes |
-
2011
- 2011-03-10 CN CN201710321015.1A patent/CN107308125B/zh active Active
- 2011-03-10 NZ NZ703564A patent/NZ703564A/en unknown
- 2011-03-10 JP JP2011052316A patent/JP6143409B2/ja active Active
- 2011-03-10 KR KR1020187030676A patent/KR101982482B1/ko active Active
- 2011-03-10 PE PE2012001538A patent/PE20130063A1/es active IP Right Grant
- 2011-03-10 MX MX2012009125A patent/MX349145B/es active IP Right Grant
- 2011-03-10 BR BR112012022873-0A patent/BR112012022873B1/pt active IP Right Grant
- 2011-03-10 KR KR1020127026488A patent/KR101913102B1/ko active Active
- 2011-03-10 MX MX2015010803A patent/MX368805B/es unknown
- 2011-03-10 MA MA35290A patent/MA34146B1/fr unknown
- 2011-03-10 GE GEAP201112868A patent/GEP201606550B/en unknown
- 2011-03-10 SG SG10201501821RA patent/SG10201501821RA/en unknown
- 2011-03-10 UA UAA201602306A patent/UA123856C2/uk unknown
- 2011-03-10 PH PH1/2012/501622A patent/PH12012501622A1/en unknown
- 2011-03-10 CA CA2789798A patent/CA2789798C/en active Active
- 2011-03-10 SG SG10201606618PA patent/SG10201606618PA/en unknown
- 2011-03-10 NZ NZ702826A patent/NZ702826A/en unknown
- 2011-03-10 TW TW105105359A patent/TWI605814B/zh active
- 2011-03-10 WO PCT/US2011/027913 patent/WO2011112816A1/en not_active Ceased
- 2011-03-10 MY MYPI2012003442A patent/MY160727A/en unknown
- 2011-03-10 AR ARP110100757A patent/AR080491A1/es unknown
- 2011-03-10 NZ NZ601595A patent/NZ601595A/en unknown
- 2011-03-10 SG SG2012057261A patent/SG183133A1/en unknown
- 2011-03-10 TW TW100108143A patent/TWI589293B/zh active
- 2011-03-10 AU AU2011224275A patent/AU2011224275B2/en active Active
- 2011-03-10 EA EA201270741A patent/EA029096B1/ru unknown
- 2011-03-10 US US13/045,108 patent/US8524276B2/en active Active
- 2011-03-10 CN CN201180013511.1A patent/CN102918039B/zh active Active
- 2011-03-11 EP EP11157837.3A patent/EP2371357B1/en active Active
- 2011-03-11 EP EP17153285.6A patent/EP3178472B1/en active Active
- 2011-03-11 ES ES11157837.3T patent/ES2623926T3/es active Active
- 2011-03-11 PL PL11157837T patent/PL2371357T3/pl unknown
- 2011-03-11 PL PL17153285T patent/PL3178472T3/pl unknown
- 2011-03-11 HU HUE11157837A patent/HUE033133T2/en unknown
- 2011-10-03 UA UAA201211733A patent/UA111717C2/uk unknown
-
2012
- 2012-08-02 TN TNP2012000392A patent/TN2012000392A1/en unknown
- 2012-08-07 CL CL2012002192A patent/CL2012002192A1/es unknown
- 2012-08-14 IL IL221452A patent/IL221452A/en active IP Right Grant
- 2012-08-23 GT GT201200247A patent/GT201200247A/es unknown
- 2012-09-19 CR CR20120476A patent/CR20120476A/es unknown
- 2012-10-02 EC ECSP12012208 patent/ECSP12012208A/es unknown
- 2012-10-10 CO CO12178897A patent/CO6630134A2/es unknown
-
2013
- 2013-07-31 US US13/956,050 patent/US9314461B2/en active Active
- 2013-08-14 US US13/966,779 patent/US8956651B2/en active Active
-
2015
- 2015-09-10 JP JP2015178184A patent/JP2016029054A/ja active Pending
-
2016
- 2016-03-15 US US15/070,555 patent/US20160206612A1/en not_active Abandoned
-
2017
- 2017-08-07 JP JP2017152275A patent/JP6429955B2/ja active Active
-
2018
- 2018-10-30 JP JP2018203748A patent/JP6647368B2/ja active Active
- 2018-12-13 US US16/219,159 patent/US10376505B2/en active Active
- 2018-12-13 US US16/219,681 patent/US10307417B2/en active Active
- 2018-12-18 ZA ZA2018/08498A patent/ZA201808498B/en unknown
-
2019
- 2019-06-24 US US16/450,157 patent/US10507206B2/en active Active
- 2019-10-25 US US16/664,239 patent/US20200121673A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000392A1 (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| IN2014DN10670A (enExample) | ||
| EA201201263A1 (ru) | Фармацевтическая композиция, содержащая этексилат дабигатрана | |
| MX369121B (es) | Formulacion farmaceutica acuosa de tapentadol para administracion oral. | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| EA201290984A1 (ru) | Гелеобразные фармацевтические композиции, препятствующие злоупотреблению | |
| EP2629786A4 (en) | COMPOSITIONS FOR THE ADMINISTRATION OF MEDICAMENTS | |
| MX2012007375A (es) | 3-ceto-n-propargil 1-aminoindano. | |
| WO2012009723A8 (en) | C-met modulator pharmaceutical compositions | |
| MY187718A (en) | Pharmaceutical formulations | |
| CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη | |
| MX347105B (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona. | |
| IN2015DN03984A (enExample) | ||
| MX2013001985A (es) | Formulaciones a base de nalbufina y sus usos | |
| PL2560612T3 (pl) | Sposób wytwarzania kompozycji farmaceutycznych do doustnego podawania zawierających jeden lub więcej składników czynnych oraz kompozycje je zawierające | |
| MX344473B (es) | Composicion farmaceutica acuosa semisolida que contiene tapentadol. | |
| MX343689B (es) | Formulaciones combinadas de darunavir. | |
| MX341976B (es) | Formulaciones de darunavir. | |
| WO2012074830A3 (en) | Modified release tranexamic acid formulation | |
| MX2014013664A (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida. | |
| MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
| PH12013500210A1 (en) | Highly crystalline valsartan | |
| TR201009399A2 (tr) | Hızlı çözünen efervesan rosuvastatin formülasyonları. | |
| WO2012108794A3 (ru) | Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии | |
| MX2012014969A (es) | Composiciones farmaceuticas estables de amlodipina con telmisartan. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |